See more : MYND Life Sciences Inc. (MYND.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Think Research Corporation (THKKF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Think Research Corporation, a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Giant Manufacturing Co., Ltd. (9921.TW) Income Statement Analysis – Financial Results
- Eagle Eye Solutions Group plc (EYE.L) Income Statement Analysis – Financial Results
- Medibank Private Limited (MPL.AX) Income Statement Analysis – Financial Results
- Alnylam Pharmaceuticals, Inc. (DUL.DE) Income Statement Analysis – Financial Results
- MegaStudyEdu Co. Ltd (215200.KQ) Income Statement Analysis – Financial Results
Think Research Corporation (THKKF)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.thinkresearch.com/ca/
About Think Research Corporation
Think Research Corporation, together with its subsidiaries, gathers, develops, and delivers knowledge-based Software-as-a-Service solutions for the health care industry in Canada, the United States, and internationally. The company's products portfolio comprises order sets that structures clinical pathway at the point of care; eReferrals that allows physicians to find and refer specialists directly from EMR systems; VirtualCare, which allows clinicians and allied health professionals to replace in-person appointments with virtual visits; and eForms, a real-time analytics to track resident volumes, signature adherence, and compliance; and COVID-19 clinical tools, as well as clinical support tools for long-term care. Think Research Corporation is based in Toronto, Canada.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 78.60M | 47.79M | 19.44M |
| Cost of Revenue | 41.22M | 23.39M | 7.51M |
| Gross Profit | 37.39M | 24.40M | 11.93M |
| Gross Profit Ratio | 47.56% | 51.05% | 61.36% |
| Research & Development | 6.78M | 6.57M | 4.45M |
| General & Administrative | 26.96M | 23.01M | 10.68M |
| Selling & Marketing | 9.09M | 8.65M | 3.70M |
| SG&A | 36.05M | 31.66M | 14.38M |
| Other Expenses | 0.00 | 0.00 | 309.00K |
| Operating Expenses | 57.23M | 46.22M | 20.79M |
| Cost & Expenses | 98.45M | 69.61M | 28.30M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.98M | 2.05M | 1.49M |
| Depreciation & Amortization | 14.40M | 7.99M | 1.96M |
| EBITDA | -5.44M | -13.83M | -6.90M |
| EBITDA Ratio | -6.92% | -28.94% | -35.49% |
| Operating Income | -19.84M | -21.82M | -8.86M |
| Operating Income Ratio | -25.24% | -45.65% | -45.55% |
| Total Other Income/Expenses | -4.09M | -6.64M | 305.00K |
| Income Before Tax | -27.91M | -30.51M | -10.04M |
| Income Before Tax Ratio | -35.50% | -63.84% | -51.64% |
| Income Tax Expense | -2.16M | -1.46M | -24.00K |
| Net Income | -25.74M | -29.05M | -10.02M |
| Net Income Ratio | -32.75% | -60.78% | -51.51% |
| EPS | -0.42 | -0.62 | -0.28 |
| EPS Diluted | -0.42 | -0.62 | -0.28 |
| Weighted Avg Shares Out | 60.87M | 46.75M | 35.87M |
| Weighted Avg Shares Out (Dil) | 60.87M | 46.75M | 35.87M |
Think Research partners with Caredove to expand access to eReferral Network in Ontario's northeast through Hubly integration engine
Canaccord Genuity repeats 'Speculative Buy' rating and $2.00 price target on Think Research after its Q1 results beat expectations
Think Research reports record first-quarter revenue as software and data solutions business continues to grow
Think Research expects to realize $9M in cost synergies by end-2022
Think Research enters $4.1M content and learning management agreement with global pharmaceutical company
Think Research on a mission to become an essential data service for clinicians everywhere
Think Research closes initial advance of $10 million from Beedie Investments under non-revolving term convertible loan facility
Source: https://incomestatements.info
Category: Stock Reports